Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab
Radiation-induced sarcoma (RIS) has been reported as a late secondary malignancy following radiotherapy for various types of cancer with a median latency of 10 years. We describe an early RIS that developed in an adolescent within three years of treatment (including PD-L1 check-point inhibitor Nivol...
Main Authors: | Lukas Šalaševičius, Goda Elizabeta Vaitkevičienė, Ramunė Pasaulienė, Rosita Kiudelienė, Ernesta Ivanauskaitė-Didžiokienė, Donatas Vajauskas, Nemira Jurkienė, Jelena Rascon |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1010-660X/56/4/155 |
Similar Items
-
Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01) -
Durability Results of Treatment with Brentuximab Vedotin in Combination with Nivolumab in Patient with Relapsed or Refractory Hodgkin Lymphoma
by: Minhas, Ahmed, et al.
Published: (2020) -
Efficacy and safety of nivolumab in the treatment of relapsed/refractory classical Hodgkin’s lymphoma: Pavlov First Saint Petersburg State Medical University experience
by: K. V. Lepik, et al.
Published: (2019-01-01) -
Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01) -
PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma
by: EA Demina
Published: (2018-07-01)